When Abivax released stunning phase 3 results for ulcerative colitis, its 600% stock price surge froze Euronext for 45 minutes.
Philip meets Abivax CEO Marc de Garidel in Vienna, Austria, to go behind the scenes of a remarkable biotech turnaround.
Marc discusses the processes involved in executing the phase 3 trial that beat even Abivax’s own phase 2 data. He also talks about France’s biotech ecosystem and the importance of having the right team.
⭐️ ABOUT THE SPEAKER
Marc de Garidel joined Abivax as CEO in 2023. Prior to this, he led two biotech companies through billion-dollar exits (CinCor Pharma and Corvidia Therapeutics). He also served as CEO of Ipsen from 2010 to 2016, and has worked at the likes of Amgen and Eli Lilly.
🔗 LINKS MENTIONED
- Abivax’s website – https://www.abivax.com/
- Phase 3 results – https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week
- $747.5 million public offering – https://ir.abivax.com/news-releases/news-release-details/abivax-announces-closing-7475-million-public-offering
- Marc de Garidel, Abivax | How to make two Billion-dollar exits (“smoothly”) | E09 – https://flot.bio/episode/marc-de-garidel-abivax-exit/
- Chris Martin, Verona Pharma 🇬🇧 | Ohtuvayre, COPD, Execution | E34 – https://flot.bio/episode/chris-martin-verona-pharma-copd/
- Christophe Bourdon, LEO Pharma 🇩🇰 | Biopharma Turnaround | E31
- https://flot.bio/episode/christophe-bourdon-leo-pharma-biopharma/
- Nanobiotix episode – https://www.youtube.com/watch?v=3Krhyy6a-nw&pp=0gcJCQMKAYcqIYzv
- Fabrice Chouraqui, Pharming 🇳🇱 | Transgenic Rabbits, Rare Diseases | E43 – https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/
📖 SHORT BLOGS BASED ON THIS EPISODE:
- Abivax’s Record NASDAQ Stock Surge After Phase 3 Data: https://flot.bio/abivax-biotech-stock-phase-3/
Transcript (coming soon)
